Introduction
============

Ovarian cancer (OC) is the most common gynecological malignancy in China, with an estimated 52,100 incident cases diagnosed and \>22,500 mortalities in China in 2015 ([@b1-ol-0-0-8954]). Despite advances in its treatment, including surgery, chemotherapy and radiotherapy, survival rates remain poor for the majority of patients, with a 5-year survival rate of \~30% ([@b2-ol-0-0-8954]). Therefore, it is essential to develop novel therapeutic strategies.

MicroRNAs (miRNAs) are small non-coding RNAs measuring 19--22 nucleotides in length that regulate gene expression by binding to complementary sequences in the 3′untranslated region (UTR) of genes, leading to either the inhibition of translation or degradation of the gene transcript ([@b3-ol-0-0-8954]). Increasing evidence has suggested that miRNAs are involved in OC development and progression. For example, Yang *et al* ([@b4-ol-0-0-8954]) demonstrated that miR-23a was upregulated in OC cells, and that it promoted the proliferation, migration and invasion, but repressed apoptosis, of OC cells through the downregulation of the expression of the tumor suppressor gene Suppression of tumorigenicity 7 like, and activation of the Wnt signaling pathways. Shen *et al* ([@b5-ol-0-0-8954]) demonstrated that miR-26a was overexpressed in human OC specimens: Ectopic expression of miR-26a increased OC cell proliferation and clonal formation through the inhibition of estrogen receptor (ER)-α, which was also confirmed in nude mice. Dong *et al* ([@b6-ol-0-0-8954]) demonstrated that OC tissues exhibited significantly decreased levels of miR-137 and miR-34a when compared with adjacent normal tissues, resulting in a trend towards poorer survival. Additionally, using luciferase assays, miR-137 and miR-34a were demonstrated to inhibit epithelial-to-mesenchymal transition and cell invasion by acting as direct suppressors of zinc finger protein SNAI1 in OC cells ([@b6-ol-0-0-8954]). Therefore, miRNAs may be potential targets in OC treatment.

In addition to being present intracellularly, miRNAs may also be secreted extracellularly through membrane-bound vesicles, including exosomes. It has been suggested that exosomal miRNAs may transfer phenotypic traits from the cancer cells of origin into surrounding normal cells, and therefore facilitate tumorigenesis and progression ([@b7-ol-0-0-8954]). For example, Baroni *et al* ([@b8-ol-0-0-8954]) observed that the transfer of breast cancer-secreted miR-9 to normal fibroblasts via exosomes increased the migration and invasion capabilities of recipient normal fibroblasts, contributing to the formation of cancer-associated fibroblasts. Treatment with exosomes derived from metastatic breast cancer MDA-MB-231 cells, including the highly-expressed miR-10b when compared with non-metastatic breast cancer MCF-7 cells or non-malignant breast HMLE or MCF-10A cells, was also observed to induce the invasive ability of non-malignant mammary epithelial cells ([@b9-ol-0-0-8954]). Therefore, targeting miRNAs in cancer cells and their exosomes may represent a more effective approach for OC treatment.

At present, miRNAs of OC in exosomes have rarely been investigated ([@b10-ol-0-0-8954]). Ying *et al* ([@b11-ol-0-0-8954]) proposed that OC-derived exosomes may release miR-222-3p into macrophages and induce polarization of the M2 phenotype, a tumor-associated macrophage-like phenotype, via inhibiting the suppressor of cytokine signalling-3/signal transducer and activator of transcription-3 pathway, which then promoted the growth and metastasis of OC. Using the microarray data, Kanlikilicer *et al* ([@b12-ol-0-0-8954]) compared the miRNAs profiles of OC cells with their exosomes, and indicated that miR-6126 was released from OC cells via exosomes. miR-6126 also significantly decreased the tube-forming, invasive and migratory abilities of OC cells *in vitro* and inhibited tumor growth (with smaller tumor size and lower weight), cell number (fewer numbers of Ki67-positive cells) and microvessel density (fewer CD31-positive cells) *in vivo* by inhibiting integrin-β1 ([@b12-ol-0-0-8954]). However, these studies did not investigate the common miRNAs in OC cells or their exosomes compared with normal cells, which was the aim of the present study. The present study preliminarily identified that miR-127-3p, miR-339-5p, miR-409-3p and miR-654-3p were commonly differentially expressed in OC cells and their exosomes and therefore may be underlying important targets for the treatment of OC ([@b13-ol-0-0-8954]).

Materials and methods
=====================

### Data collection

The Affymetrix miRNA microarray data (accession number GSE76449) were collected from the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) ([@b12-ol-0-0-8954]), in which exosomal samples isolated from 6 human epithelial OC \[SKOV3_ip1; A2780_PAR, HEYA8, SKOV3_TR (Taxol-resistant), A2780_CP20 (cisplatin-resistant) and HEYA8_MDR (multidrug-resistant)\] cell lines, 1 normal ovarian surface epithelial HIO180 cell line and their original cell samples were downloaded. Each sample had 2 biological repeats, resulting in a total of 28 samples. To simplify the present study, and to exclude the effects of chemotherapy drugs including paclitaxel and cisplatin which were been used in the study of Kanlikilicer *et al* ([@b12-ol-0-0-8954]), only the exosomal and original cell samples in the chemo-sensitive OC cells (SKOV3_ip1, A2780_PAR and HEYA8) and normal cells (n=16) were included in the present study to reveal the mechanism and underlying treatment targets for OC.

### Data normalization and identification of differentially-expressed miRNAs (DE-miRNAs)

The raw data (CEL files) downloaded from the Affymetrix Multispecies miRNA-4 Array platform GPL19117 were preprocessed, including background correction log2 transformation and quantile normalization, using the Robust Multiarray Average function available in the Bioconductor package (version 1.34.2; <http://www.bioconductor.org/packages/release/bioc/html/limma.html>). The DE-miRNAs between cancer and normal cells were identified using the Linear Models for Microarray data method ([@b14-ol-0-0-8954]) in the Bioconductor R package (version 3.32.5; <http://www.bioconductor.org/packages/release/bioc/html/limma.html>). miRNAs with P\<0.05 and \|log fold change (FC)\| \>1 were considered differentially expressed. To visualize the shared DE-miRNAs between different cell types and between exosomes and their cells of origin, a Venn diagram was generated using a web-based tool accessed September 2017 (<http://bioinformatics.psb.ugent.be/webtools/Venn/>).

### Target genes prediction and functional enrichment analysis

mRNA targets of the DE-miRNAs were predicted using the miRWalk2 database (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>), which contains 12 bioinformatic algorithms: Microt4; miRWalk; mirbridge; miRanda; miRDB; miRMap; Pictar2; PITA; miRNAMap; RNAhybrid; RNA22; and Targetscan. Targets were selected when they overlapped in at least 4 of 12 databases. Then, the miRNA-target gene interaction network was constructed and visualized using Cytoscape software (version 2.8; [www.cytoscape.org/](www.cytoscape.org/)) ([@b15-ol-0-0-8954]).

The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for these target genes were analyzed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool (version 6.8; <http://david.abcc.ncifcrf.gov>) ([@b16-ol-0-0-8954]). P\<0.05 was set as the cut-off value.

### Validation of the association between crucial miRNAs, target genes and clinical characteristics

The miRNASeq data of OC (Level 3) was obtained from The Cancer Genome Atlas (TCGA; <https://tcga-data.nci.nih.gov/>; accessed January 2018) to confirm the potential associations between crucial miRNAs and clinical characteristics, including age, tumor stage, tumor grade, residual tumor, overall survival (OS) and disease-free survival (DFS).

Raw counts in TCGA were converted to log-counts per million (CPM) values using the CPM function in edgeR (version 3.4; <http://www.bioconductor.org/packages/release/bioc/html/edgeR.html>) and normalized using the trimmed mean of M-values algorithm. The preprocessed data were transformed into the gene expression matrix using the voom/Limma R-package (version 3.32.5; <http://bioconductor.org/packages/release/bioc/html/limma.html>), and then the targeted miRNAs were selected.

The OC samples were dichotomously grouped according to their clinical characteristics (age, ≥60 vs. \<60; stage, I--II vs. stage III--IV; histologic tumor grade, 1--2 vs. 3--4; with tumor vs. tumor-free) and the differences in the expression of the aforementioned miRNAs between the two groups were analyzed by an independent t-test. OC samples were staged or graded according to the International Federation of Gynecology and Obstetrics (FIGO) staging ([@b17-ol-0-0-8954]) or a universal histological grading system ([@b18-ol-0-0-8954]). The samples with survival data were assigned to two groups based on the expression of each miRNA (low or high expression level). The threshold for the expression group was the median miRNA expression in each samples (high-expression group ≥median; low-expression group \<median). The Kaplan-Meier method with the log-rank test was performed using GraphPad Prism software (version 5; GraphPad Software, Inc., La Jolla, CA, USA) to estimate the difference in DFS and OS between the high and low expression groups. P\<0.05 was considered to indicate a statistically significant difference.

Furthermore, the clinical associations of miRNAs and mRNA, and the association between miRNA and target genes, were also examined by searching the LinkedOmics database (<http://www.linkedomics.org/>), which contains multi-omics data and clinical data for 32 cancer types and a total of 11,158 patients from the TCGA project ([@b19-ol-0-0-8954]). In the LinkedOmics database, the clinical associations of miRNAs and mRNAs, and the association between miRNAs and target genes was directly calculated using Cox\'s Regression test and Pearson\'s correlation test, respectively ([@b19-ol-0-0-8954]).

Results
=======

### Identification of DE-miRNAs between OC and normal control cells

For the exosomal samples, a total of 661 DE-miRNAs were identified between SKOV3_ip1 and HIO180 cells, according to the threshold of P\<0.05 and \|logFC\| \>1, including 494 upregulated and 167 downregulated; 141 DE-miRNAs were identified between A2780 \_PAR and HIO180 cells, including 74 upregulated and 66 downregulated; and 492 DE-miRNAs were identified between HEYA8 and HIO180 cells, including 262 upregulated and 230 downregulated. These data indicated different profiles of exosomal miRNAs in different cancer cell lines compared with the normal controls ([@b10-ol-0-0-8954]). To investigate the underlying mechanisms in the development of OC, common miRNAs among the 3 OC cell lines (SKOV3_ip1, A2780 \_PAR, and HEYA8, selected as they were not influenced by chemotherapy) were screened by a Venn diagram analysis ([Fig. 1](#f1-ol-0-0-8954){ref-type="fig"}). As a result, 12 upregulated and 12 downregulated DE-miRNAs were respectively identified to be shared by the exosomes of these 3 OC cell lines ([Table I](#tI-ol-0-0-8954){ref-type="table"}).

From the original cell samples, a total of 408 DE-miRNAs were identified between SKOV3_ip1 and HIO180 cell lines, including 102 upregulated and 306 downregulated; 426 DE-miRNAs were identified between A2780 \_PAR and HIO180 cell lines, including 148 upregulated and 278 downregulated; and 357 DE-miRNAs were identified between HEYA8 and HIO180 cell lines, including 159 upregulated and 198 downregulated. Following the Venn diagram analysis ([Fig. 1](#f1-ol-0-0-8954){ref-type="fig"}), 5 upregulated and 65 downregulated DE-miRNAs were identified to be common among the 3 OC cell lines ([Table II](#tII-ol-0-0-8954){ref-type="table"}).

In addition, the number of upregulated genes was increased compared with the number of downregulated genes in the exosomes in each cell line, but the opposite was identified in their original cells, suggesting an overexpression of oncogenes and a decreased expression of tumor-suppressor genes may be the primary mechanisms for exosomal and original cells, respectively, to promote the development and progression of OC. This appeared to be consistent with the established theory that exosomes may transfer certain oncogenic DE-miRNAs into the extracellular environment to maintain and promote tumorigenesis ([@b9-ol-0-0-8954]). To additionally investigate the differences or similarities in DE-miRNAs between exosomes and their original cells during cancer development, a Venn diagram analysis was performed. The results demonstrated that only 9 downregulated DE-miRNAs were shared between the exosomes and original cells ([Fig. 1](#f1-ol-0-0-8954){ref-type="fig"}; [Table III](#tIII-ol-0-0-8954){ref-type="table"}), and the others were exosomal-(n=15) or original cell-specific (n=61). These data suggested that these 9 DE-miRNAs may be particularly crucial for OC development in an exosomal or non-exosomal manner.

### Target genes for DE-miRNAs between OC cells and normal controls

Following the use of 6 algorithms, only the target genes for 1 upregulated (hsa-miR-940) and 4 shared downregulated (hsa-miR-127-3p, hsa-miR-339-5p, hsa-miR-409-3p and hsa-miR-654-3p) DE-miRNAs of exosomes from 3 OC cells were obtained. From the original cells of the 3 OC cell lines, only the target genes for 1 upregulated (hsa-miR-17-5p) and 19 shared downregulated (hsa-miR-127-3p, hsa-miR-127-5p, hsa-miR-140-3p, hsa-miR-140-5p, hsa-miR-184, hsa-miR-299-3p, hsa-miR-299-5p, hsa-miR-337-5p, hsa-miR-339-5p, hsa-miR-409-3p, hsa-miR-409-5p, hsa-miR-485-5p, hsa-miR-543, hsa-miR-574-3p, hsa-miR-604, hsa-miR-654-3p, hsa-miR-654-5p, hsa-miR-767-5p and hsa-miR-935) DE-miRNAs were predicted. Among them, downregulated hsa-miR-127-3p, hsa-miR-339-5p, hsa-miR-409-3p and hsa-miR-654-3p were common between exosomes and their original cells. The regulatory network of these common miRNAs and their target genes is presented in [Fig. 2](#f2-ol-0-0-8954){ref-type="fig"}.

### Functional enrichment analysis of common DE-miRNAs in exosomes and their original cells

The target genes of the 4 shared downregulated DE-miRNAs between exosomes and their corresponding original cells were analyzed using DAVID for functional enrichment analysis. It was revealed that 6 KEGG pathways were enriched, including the Wnt signaling pathway \[hsa-miR-409-3p-Wnt family member 7A (WNT7A), hsa-miR-339-5p-Wnt family member 3A (WNT3A), hsa-miR-654-3p-VANGL planar cell polarity protein 2 (VANGL2), hsa-miR-409-3p-C-terminal binding protein 1 (CTBP1) and hsa-miR-339-5p-chromodomain helicase DNA-binding protein 8 (CHD8)\], Proteoglycans in cancer \[hsa-miR-127-3p- serine/threonine-protein phosphatase PP1α catalytic subunit (PPP1CA), hsa-miR-127-3p-urokinase (PLAU)\], and Insulin resistance (hsa-miR-654-3p-ribosomal protein S6 kinase α1; [Table IV](#tIV-ol-0-0-8954){ref-type="table"}).

### Validation of the association between crucial miRNAs, target genes and clinical characteristics

To validate the clinical importance of the identified miRNAs of the present study, the miRNA expression and clinical data associated with OC were also extracted from the TCGA database. As a result, miRNA expression data were available for 489 patients, but clinical data for age, tumor stage, tumor grade, residual tumor, OS and DFS were obtained from only 481, 281, 472, 431, 485 and 410 women, respectively. The results indicated that the expression of hsa-miR-127 in patients with higher-grade tumors (G3-G4) was significantly decreased compared with that in patients with lower grades (G1-G2) (11.06±1.09 vs. 10.71±1.53; P=0.03; [Fig. 3](#f3-ol-0-0-8954){ref-type="fig"}). However, no significant difference in miRNA expression was observed when patients were stratified by age, tumor stage and presence of residual tumors ([Table V](#tV-ol-0-0-8954){ref-type="table"}). Kaplan-Meier analysis also indicated that these miRNAs were not suitable for use as prognostic factors for survival outcomes in patients with OC ([Fig. 4](#f4-ol-0-0-8954){ref-type="fig"}), which was also confirmed by LinkedOmics analysis using 453 overlapping samples from the miRNASeq and clinical datasets (hsa-miR-409-3p, P=0.296; hsa-miR-339-5p, P=0.426; hsa-miR-127-3p, P=0.122; has-miR-654, P=0.071).

A Pearson correlation test using 287 overlapping samples from the miRNASeq and RNAseq datasets validated the significant negative correlation between hsa-miR-409-3p and CTBP1 (r=−0.150, P=0.011), hsa-miR-339-5p and CHD8 (r=−0.125, P=0.033) and hsa-miR-127-3p and PPP1CA (r=−0.201, P=0.0006), but not the others. These target genes were also not significantly associated with survival outcomes (CTBP1, P=0.966; CHD8, P=0.224; PPP1CA, P=0.333), as demonstrated by a cox regression test using 303 overlapping samples from the RNAseq and clinical datasets.

Discussion
==========

Although all 3 DE-miRNAs (hsa-miR-127-3p, hsa-miR-339-5p and hsa-miR-409-3p) have been demonstrated to have a tumor-suppressive role in cancer ([@b20-ol-0-0-8954]), only miR-127-3p ([@b21-ol-0-0-8954]) and miR-339-5p ([@b22-ol-0-0-8954]) had been identified in OC cells in previous studies. miR-127-3p was demonstrated to be downregulated in OC cell lines and OC tumor tissues; lentiviral-mediated miR-127-3p reduced the proliferation and invasion of OVCAR-3 and Caov-3 cells by directly inhibiting the Bcl-associated athanogene 5 (BAG5) gene, and subsequent BAG5 upregulation ameliorated the tumor-suppressive effects of miR-127-3p overexpression in OC ([@b21-ol-0-0-8954]). Although downregulated compared with normal cells, the expression of miR-339-5p was identified to be differentially expressed in different cell types, with the highest expression in OVCAR5 cells and lowest expression in SKOV3 cells ([@b21-ol-0-0-8954]). Inhibition of miR-339-5p expression increased the migration and invasion of OVCAR5 cells, while upregulated miR-339-5p attenuated this effect in SKOV3 cells ([@b22-ol-0-0-8954]). The validated targets of miR-339-5p were nucleus accumbens associated 1 and B-cell lymphoma-6 ([@b22-ol-0-0-8954]). In accordance with these aforementioned studies, hsa-miR-127-3p, hsa-miR-339-5p and hsa-miR-409-3p were also identified to be downregulated in the 3 OC cell lines in the present study. Among them, hsa-miR-127-3p may be particularly important in OC due to its significantly negative correlations with high tumor grades, which were identified in the present study, a key malignant characteristic of cancer.

Previous evidence has indicated that the Wnt signaling pathway is crucial for cancer progression ([@b23-ol-0-0-8954]). Yoshioka *et al* ([@b24-ol-0-0-8954]) identified abundant WNT7A in the epithelium of serous OC, but not in borderline and benign tumors, normal ovary or endometrioid carcinomas ([@b24-ol-0-0-8954]). *In vitro* analysis revealed that WNT7A may promote the malignant transformation of ovarian epithelial cells by stimulating the β-catenin/T-cell factor (TCF)-matrix metalloproteinase 7 (MMP7) signaling pathway ([@b24-ol-0-0-8954]). Stimulation of primary ovarian surface epithelium cells (OSE) *in vitro* with WNT3A also inhibited glycogen synthase kinase-3β and destabilized the adherens junction through the downregulation of epithelial (E)-cadherin and nuclear translocation of β-catenin, promoting the increased proliferative rate of OSE cells ([@b25-ol-0-0-8954]). The archetypal Wnt/planar cell polarity protein VANGL2 has been demonstrated to be overexpressed in basal breast cancer and implicated in tumor growth by activating the VANGL2-nucleoporin p62/sequestosome 1-c-Jun N-terminal kinase pathway, ultimately inducing a poor prognosis ([@b26-ol-0-0-8954]). CTBP1 was demonstrated to activate the expression of Wnt genes and downregulate their downstream E-cadherin in a TCF-independent manner ([@b27-ol-0-0-8954]). Small interfering RNA knockdown of CTBP1 restored E-cadherin expression in cancer cell lines, inhibiting their proliferation and invasion ([@b28-ol-0-0-8954]). CHD8 was previously demonstrated to inhibit the transcription of β-catenin target genes through chromatin compaction ([@b29-ol-0-0-8954]) and it may be a tumor suppressor gene ([@b30-ol-0-0-8954]). However, multiple previous studies have identified an increased expression of CHD8 in cancer cells compared with that in normal tissues ([@b31-ol-0-0-8954],[@b32-ol-0-0-8954]). Subsequent *in vitro* and *in vivo* analysis confirmed that CHD8 depletion may be detrimental to the growth of B-acute lymphoblastic leukemia cells and promote its apoptosis ([@b33-ol-0-0-8954]). The upregulation of Wnt pathway genes in cancer may be due to the downregulation of their corresponding miRNAs, which was confirmed previously: WNT7A has been demonstrated to be a direct target of miR-15b in OC using a luciferase reporter assay. The inverse correlation of a high expression of WNT7A and low-expression of miR-15b in OC was observed to be associated with decreased survival rates in patients with OC ([@b34-ol-0-0-8954]). miR-137 has been revealed to suppress the 3′ UTR luciferase-reporter activity of CTBP1, reducing its mRNA expression levels followed by increasing the expression of immediate downstream effectors of CtBP1, including E-cadherin ([@b35-ol-0-0-8954]). In the present study, it was identified that WNT7A/CTBP1, WNT3A/CHD8, and VANGL2 were respectively regulated by hsa-miR-409-3p, hsa-miR-339-5p and hsa-miR-654-3p, thereby indirectly explaining the roles of these miRNAs in OC. However, only negative regulatory associations between hsa-miR-409-3p and CTBP1, and hsa-miR-339-5p and CHD8, were verified using the OC data in TCGA, which had not been demonstrated in previous studies, to the best of our knowledge. These data indicate that these 2 miRNAs may be novel effectors in OC.

PLAU encodes for the urokinase-type plasminogen activator (uPA), which has been demonstrated to be critical for OC development and progression ([@b36-ol-0-0-8954],[@b37-ol-0-0-8954]). uPA is overexpressed in the majority of patients with OC ([@b36-ol-0-0-8954]). The overexpression of uPA has been significantly associated with poorer degrees of differentiation, higher clinical stages (III--IV), lymph node or omental metastasis and decreased survival ([@b36-ol-0-0-8954],[@b37-ol-0-0-8954]). Mechanistic studies suggested that uPA may promote the migration and invasion of OC cells by inducing the formation of vasculogenic mimicry via the Protein kinase B/mechanistic target of rapamycin/MMP2/Laminin5γ2 signaling pathway, while the use of an uPA antagonist, cyclic-arginine-glycine-aspartic acid, weakened these processes ([@b38-ol-0-0-8954]). In addition, the upregulated expression of uPA in OC cells was demonstrated to be p38 mitogen activated protein kinase (MAPK) signal-pathway dependent: The utility of p38 MAPK inhibitor SB203580 almost decreased the expression of uPA to an absolute count of 0 ([@b39-ol-0-0-8954]). Furthermore, uPA may be a target gene of miR-193b: Overexpression of miR-193b was demonstrated to negatively regulate uPA expression and thereby inhibit the invasiveness of breast ([@b40-ol-0-0-8954]), pancreatic ([@b41-ol-0-0-8954]) and prostate cancer ([@b42-ol-0-0-8954]) cells. However, to the best of our knowledge, there have been no prior studies investigating uPA-associated miRNAs in OC cells. In the present study, it was predicted that the upregulation of uPA in OC may be attributed to the downregulation of hsa-miR-127-3p. This was not verified by subsequent TCGA analysis, and therefore additional experiments may be required.

PPP1CA, encoding PP1α, is suggested to regulate critical cellular events, including cell cycle and apoptosis ([@b43-ol-0-0-8954],[@b44-ol-0-0-8954]); therefore, it may be a potential tumor-associated gene. This hypothesis has been confirmed by previous studies: For example, Hsu *et al* ([@b45-ol-0-0-8954]) identified that PPP1CA was amplified and overexpressed in oral squamous cell carcinomas cells (OSCC), and that knockdown of PP1α suppressed OSCC cell G0 growth arrest by modulating retinoblastoma phosphorylation. Nohata *et al* ([@b46-ol-0-0-8954]) also observed the overexpression of PPP1CA in clinical specimens with maxillary sinus squamous cell carcinoma (MSSCC). Silencing of the PPP1CA gene significantly inhibited cancer cell proliferation and invasion. Shastry *et al* ([@b47-ol-0-0-8954]) revealed that patients with glioblastoma with positive PP1A and p53 expression exhibited a poorer overall median time (14 months) compared with PP1A-negative cases (21 months). Accordingly, we hypothesize that PPP1CA is also highly expressed in OC. Furthermore, PP1CA was revealed to be expressed at high levels due to a frequent downregulation of miR-874 in MSSCC ([@b46-ol-0-0-8954]). However, to the best of our knowledge, no previous studies have investigated PPP1CA-associated miRNAs in OC cells. In the present study, it was predicted that the upregulation of PPP1CA in OC may be attributed to the downregulation of hsa-miR-127-3p. This negative association was also verified in the TCGA analysis.

Notably, it has been suggested that co-culture with OC ES-2 cells and incubation with ES-2-conditioned medium induced the expression of uPA mRNA in fibroblastic stromal LEP cells \~2-fold ([@b48-ol-0-0-8954]), indicating that OC cells may externally secret certain signals, including miRNAs, to regulate the expression of uPA and induce tumorigenesis. As expected, hsa-miR-127-3p was also identified to be downregulated in the exosomes of OC cells in the present study, and therefore the addition of hsa-miR-127-3p-containing exosomes may be a novel approach to the treatment of OC. Similarly, Lin *et al* ([@b49-ol-0-0-8954]) observed that exosomes derived from the conditional supernatant of the esophageal cancer KYSE410 cell line induced an increase in the cell migratory and invasive abilities of KYSE410 and 2 other esophageal carcinoma KYSE510 and YES2 cell lines, in which the Wnt/β-catenin signaling pathway was activated. Accordingly, miRNAs that regulate Wnt pathway genes in exosomes may also be downregulated. This hypothesis may be indirectly supported by data from Dempsey *et al* ([@b50-ol-0-0-8954]), who indicated that platelet exosomes were enriched for miRNAs that regulated WNT pathways. By transfecting miRs into endothelial cells, these platelet exosomal miRNAs were able to inhibit WNT signaling in endothelial cells and affect cell motility ([@b50-ol-0-0-8954]). In the present study, the expressions of hsa-miR-339-5p and hsa-miR-409-3p that regulated Wnt pathways genes were also significantly decreased in the exosomes of OC cells, indicating their potential for OC treatment through overexpression.

There are certain limitations to be acknowledged when interpreting these results. Firstly, only 3 OC cell lines were selected for screening crucial miRNAs. Therefore, the miRNAs identified here may not represent miRNA candidates that are potentially associated with all types of OC. Secondly, only 2 repeats were included in each sample of the microarray data used ([@b12-ol-0-0-8954]), which may affect the results of the statistical analysis. However, it may be acceptable to perform bioinformatics analyses, as demonstrated by several previous studies ([@b51-ol-0-0-8954],[@b52-ol-0-0-8954]). Thirdly, the TCGA data did not include the normal control, which led to several unexpected, non-significant associations between the miRNAs identified in OC cells and clinical characteristics. Additional clinical trials are required to confirm the conclusions. Fourthly, although the analysis of the present study has preliminarily demonstrated a negative association between miRNAs and their target genes (hsa-miR-409-3p and CTBP1, hsa-miR-339-5p and CHD8, and hsa-miR-127-3p and PPP1CA) in clinical samples, *in vitro* and *in vivo* experiments are necessary. Fifthly, the exosomal mechanisms of these 3 miRNAs remain uninvestigated, which require additional confirmation by using an exosome inhibitor, GW4869 ([@b53-ol-0-0-8954]).

In conclusion, the present study preliminarily revealed that hsa-miR-127-3p, hsa-miR-339-5p and hsa-miR-409-3p may be crucial for the development of OC in exosomal- and non-exosomal-based pathways. They may be involved in OC by targeted modulation of WNT (CTBP1 and CHD8) or the Proteoglycans in cancer pathway (PPP1CA) genes. Upregulation of these genes may be a potential therapeutic strategy for OC.
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![Venn diagram analyzing the common differentially-expressed microRNAs screened in 3 ovarian cancer SKOV3_ip1, A2780 \_PAR, HeyA8 cell lines and their exosomes when compared with the normal HIO180 cell line, and the difference between ovarian cancer cells and their exosomes.](ol-16-02-2391-g00){#f1-ol-0-0-8954}
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![Kaplan-Meier analysis indicating that these miRNAs are not good prognostic factors associated with survival outcomes for patients with ovarian cancer. (A) OS of miR-127; (B) DFS of miR-127; (C) OS of miR-409; (D) DFS of miR-409; (E) OS of miR-339; (F) DFS of miR-339; (G) OS of miR-654; (H) DFS of miR-654. OS, overall survival; DFS, disease free survival; miRNAs, microRNAs.](ol-16-02-2391-g03){#f4-ol-0-0-8954}

###### 

Shared DE-microRNAs of exosomes from 3 ovarian cancer A2780_PAR, HEYA8 and SKOV3_ip1 cell lines and the normal ovarian HIO180 cell line.

                                    SKOV3_ip1 vs. HIO180   A2780_PAR vs. HIO180   HEYA8 vs. HIO180                      
  --------------- ----------------- ---------------------- ---------------------- ------------------ -------- --------- -------------
  Upregulated     hsa-miR-6503-3p   1.5452                 0.0318                 4.2537             0.0107   2.2433    0.0018
                  hsa-miR-6732-5p   2.2215                 0.0052                 2.2282             0.0467   1.5404    0.0248
                  hsa-miR-1825      4.3538                 0.0001                 4.6936             0.0037   3.7560    3.72×10^−6^
                  hsa-miR-1281      3.7577                 0.0003                 3.8823             0.0033   3.0166    8.30×10^−5^
                  hsa-miR-345-3p    2.7003                 0.0016                 2.1740             0.0259   2.2642    0.0017
                  hsa-miR-6865-3p   1.8265                 0.0112                 4.5809             0.0069   2.0420    0.0042
                  hsa-miR-3613-5p   1.7880                 0.0142                 3.7595             0.0232   2.5406    0.0006
                  hsa-miR-940       3.3506                 0.0005                 4.6717             0.0095   3.2752    2.71×10^−5^
                  hsa-let-7f-1-3p   2.3675                 0.0032                 4.2317             0.0081   2.8521    0.0008
                  hsa-miR-3921      1.2914                 0.0452                 4.6335             0.0102   2.7964    0.0002
                  hsa-miR-6877-3p   1.4481                 0.0326                 4.1303             0.0205   1.7630    0.0112
                  hsa-miR-214-3p    3.3959                 0.0005                 7.3116             0.0001   1.5850    0.0235
  Downregulated   hsa-miR-127-3p    −3.2732                0.0006                 −3.8741            0.0024   −2.7713   0.0002
                  hsa-miR-654-3p    −2.4874                0.0087                 −2.7430            0.0103   −2.8694   0.0002
                  hsa-miR-376c-3p   −2.0892                0.0059                 −1.8348            0.0462   −2.6451   0.0006
                  hsa-miR-487b-3p   −2.0324                0.0069                 −3.0766            0.0073   −3.1350   6.73×10^−5^
                  hsa-miR-224-5p    −3.1803                0.0008                 −2.5920            0.0131   −4.1790   1.06×10^−6^
                  hsa-miR-6074      −1.9951                0.0332                 −2.1982            0.0303   −2.4949   0.0007
                  hsa-miR-339-5p    −4.6015                7.85×10^−5^            −2.2480            0.0377   −3.3341   2.03×10^−5^
                  hsa-miR-409-3p    −3.5353                0.0005                 −2.4868            0.0176   −2.5549   0.0006
                  hsa-miR-22-3p     −3.1810                0.0008                 −5.8766            0.0135   −1.9292   0.0061
                  hsa-miR-152-3p    −4.0552                0.0002                 −3.8035            0.0117   −2.2327   0.0019
                  hsa-miR-193a-3p   −2.5431                0.0026                 −2.9552            0.0075   −2.3664   0.0021
                  hsa-miR-381-3p    −2.6255                0.00195                −2.2307            0.0234   −2.0432   0.0040

DE-miRNAs, differentiability expressed microRNAs; FC, fold change; hsa, *Homo sapiens*; miR, microRNA.

###### 

Shared DE-miRNAs of original cells from 3 ovarian cancer A2780_PAR, HEYA8, SKOV3_ip1 cell lines and the normal ovarian HIO180 cell line. The top 20 downregulated miRNAs were listed.

                                    SKOV3_ip1 vs. HIO180   A2780_PAR vs. HIO180   HEYA8 vs. HIO180                           
  --------------- ----------------- ---------------------- ---------------------- ------------------ ------------- --------- ---------------
  Upregulated     hsa-miR-17-5p     2.2198                 0.0008                 1.8453             0.0020        1.2775    0.0163
                  hsa-miR-8057      1.3228                 0.0116                 1.0111             0.0382        1.1279    0.0340
                  hsa-miR-20b-5p    3.7411                 2.93×10^−5^            2.5826             0.0002        1.2728    0.0167
                  hsa-miR-20a-5p    2.3927                 0.0005                 1.9455             0.0011        1.3961    0.0087
                  hsa-miR-106a-5p   2.2889                 0.0006                 1.7874             0.0019        1.2947    0.0149
  Downregulated   hsa-miR-140-5p    −1.1008                0.0319                 −1.4803            0.0074        −2.8567   8.16×10^−8^
                  hsa-miR-487a-3p   −1.7013                0.0040                 −1.6719            0.0050        −2.0394   0.0001
                  hsa-miR-381-3p    −1.7169                0.0062                 −1.8955            0.0088        −2.2111   3.27×10^−5^
                  hsa-miR-377-5p    −1.8697                0.0158                 −1.0028            0.0477        −1.3828   0.0093
                  hsa-miR-1306-5p   −2.0760                0.0020                 −1.8761            0.0019        −1.7115   0.0013
                  hsa-miR-370-5p    −1.5049                0.0180                 −2.0784            0.0010        −1.5561   0.0034
                  hsa-miR-6839-5p   −1.1913                0.0186                 −1.0604            0.0473        −1.1274   0.0340
                  hsa-miR-337-5p    −2.1739                0.0024                 −2.5794            0.0024        −2.4266   5.17×10^−6^
                  hsa-miR-604       −1.1959                0.0249                 −1.6227            0.0032        −1.049    0.0486
                  hsa-miR-493-3p    −2.7845                0.0002                 −2.5499            0.0038        −3.3224   4.54×10^−10^
                  hsa-miR-758-3p    −2.2183                0.0039                 −2.0373            0.0008        −1.8360   0.0006
                  hsa-miR-127-5p    −2.5959                0.0028                 −2.3487            0.0015        −1.9215   0.0003
                  hsa-mir-381       −1.5770                0.0089                 −1.7904            0.0045        −1.6309   0.0022
                  hsa-miR-6508-5p   −1.1225                0.0339                 −1.0228            0.0309        −1.2049   0.0235
                  hsa-miR-134-5p    −4.5744                2.96×10^−5^            −3.7451            1.36×10^−5^   −4.2165   2.76×10^−15^
                  hsa-miR-487b-3p   −5.1189                4.09×10^−6^            −5.5027            8.78×10^−7^   −5.3287   2.17×10^−23^
                  hsa-miR-323a-3p   −1.4376                0.0090                 −1.1565            0.0203        −1.8147   0.0006
                  hsa-miR-411-3p    −1.9974                0.0022                 −1.6534            0.0029        −1.4233   0.0075
                  hsa-miR-196b-5p   −3.2357                0.0017                 −2.2388            0.0005        −3.5772   1.95 ×10^−11^
                  hsa-miR-370-3p    −1.6817                0.0223                 −1.3440            0.0090        −2.1430   5.66×10^−5^

DE-miRNAs, differentiability expressed microRNAs; FC, fold change; hsa, *Homo sapiens*; miR, microRNA.

###### 

Shared DE-microRNAs between exosomes and original cells.

                               SKOV3_ip1 vs. HIO180   A2780_PAR vs. HIO180   HEYA8 vs. HIO180                           
  ---------- ----------------- ---------------------- ---------------------- ------------------ ------------- --------- -------------
  Exosomes   hsa-miR-127-3p    −3.2732                0.0006                 −3.8741            0.0024        −2.7712   0.0002
             hsa-miR-654-3p    −2.4874                0.0087                 −2.7430            0.0103        −2.8694   0.0002
             hsa-miR-376c-3p   −2.0893                0.0059                 −1.8348            0.0462        −2.6451   0.0006
             hsa-miR-487b-3p   −2.0324                0.0069                 −3.0766            0.0073        −3.1350   6.73×10^−5^
             hsa-miR-224-5p    −3.1803                0.0008                 −2.5920            0.0131        −4.1790   1.06×10^−6^
             hsa-miR-339-5p    −4.6015                7.85×10^−5^            −2.2480            0.0377        −3.3341   2.03×10^−5^
             hsa-miR-409-3p    −3.5353                0.0005                 −2.4868            0.0176        −2.5549   0.0006
             hsa-miR-152-3p    −4.0552                0.0002                 −3.8035            0.0117        −2.2327   0.0019
             hsa-miR-381-3p    −2.6255                0.0020                 −2.2307            0.0234        −2.0432   0.0040
  Original   hsa-miR-127-3p    −6.8163                5.78×10^−37^           −6.5228            1.42×10^−6^   −7.0302   3.31×10^−7^
             hsa-miR-654-3p    −3.4292                1.25×10^−10^           −3.1935            0.0006        −4.0444   6.68×10^−5^
             hsa-miR-376c-3p   −2.6295                7.89×10^−7^            −2.0037            0.0062        −1.6068   0.0039
             hsa-miR-487b-3p   −5.3287                2.17×10^−23^           −5.1189            4.09×10^−6^   −5.5027   8.78×10^−7^
             hsa-miR-224-5p    −2.6302                7.84×10^−7^            −5.7820            1.89×10^−6^   −4.4687   8.52×10^−6^
             hsa-miR-339-5p    −2.0021                0.0002                 −1.2081            0.0175        −1.3532   0.0118
             hsa-miR-409-3p    −6.0879                6.24×10^−30^           −6.4526            7.75×10^−7^   −5.2779   3.65×10^−6^
             hsa-miR-152-3p    −4.7885                3.13×10^−19^           −2.8237            0.0003        −2.8109   0.0002
             hsa-miR-381-3p    −2.2111                3.27×10^−05^           −1.7169            0.0062        −1.8955   0.0088

DE-miRNAs, differentiability expressed microRNAs; FC, fold change; hsa, *Homo sapiens*; miR, microRNA.

###### 

Function enrichment for target genes of 4 common differentially-expressed microRNAs in exosomes and their original cells of ovarian cancer.

  KEGG IDs   Pathway name                                      P-value   Genes
  ---------- ------------------------------------------------- --------- ----------------------------------------------------------------------------------------------------------------
  hsa00430   Taurine and hypotaurine metabolism                0.0068    GAD2, BAAT, GGT1, GAD1
  hsa05205   Proteoglycans in cancer                           0.0077    CAV1, TNF, ERBB4, MRAS, PPP1R12B, MMP9, WNT3A, PPP1R12C, PLAUR, AKT1, PPP1CA, CDKN1A, HPSE2, CD44, WNT7A, PLAU
  hsa04310   Wnt signaling pathway                             0.0139    CTNNBIP1, CHD8, CTBP1, WNT3A, VANGL2, WIF1, BAMBI, DAAM1, TBL1X, WNT7A, TCF7L2, TCF7L1
  hsa05412   Arrhythmogenic right ventricular cardiomyopathy   0.0162    ITGA9, ACTN4, ITGA7, SGCD, CACNB4, TCF7L2, TCF7L1, CTNNA2
  hsa04931   Insulin resistance                                0.0483    AKT1, PRKCZ, PPP1CA, TNF, PTPRF, RPS6KA1, CREB5, SLC27A2, SLC27A4
  hsa04520   Adherens junction                                 0.0485    PTPRF, ACTN4, SORBS1, CTNND1, TCF7L2, TCF7L1, CTNNA2

KEGG, Kyoto encyclopedia of genes and genomes; hsa, *Homo sapiens*.

###### 

Associations between miRNAs and clinical characteristics analyzed using data from The Cancer Genome Atlas data.

  Characteristics                                                   hsa-miR-127   P-value   hsa-miR-339   P-value   hsa-miR-409   P-value   hsa-miR-654   P-value
  ----------------------------------------------------------------- ------------- --------- ------------- --------- ------------- --------- ------------- ---------
  Age                                                                                                                                                     
    ≥60 (n=28)                                                      10.74±1.49    0.97      6.88±0.92     0.63      5.31±1.40     0.82      4.73±1.47     0.92
    \<60 (n=453)                                                    10.75±1.46              6.83±0.98               5.29±1.32               4.74±1.49     
  FIGO stage^[a](#tfn5-ol-0-0-8954){ref-type="table-fn"}^                                                                                                 
    I--II (n=28)                                                    10.10±1.98    0.08      6.61±1.32     0.16      4.81±1.43     0.05      4.18±1.79     0.95
    III--IV (n=253)                                                 10.79±1.43              6.87±0.92               5.33±1.35               4.77±1.46     
  Histological grade^[a](#tfn5-ol-0-0-8954){ref-type="table-fn"}^                                                                                         
    1--2 (n=57)                                                     11.06±1.09    0.03      6.64±0.82     0.06      5.58±1.15     0.11      4.98±1.20     0.19
    3--4 (n=415)                                                    10.71±1.53              6.88±0.95               5.26±1.40               4.70±1.53     
  Residual tumor^[a](#tfn5-ol-0-0-8954){ref-type="table-fn"}^                                                                                             
    Present (n=317)                                                 10.80±1.39    0.27      6.85±0.96     0.65      5.35±1.33     0.45      4.81±1.36     0.26
    Absent (n=114)                                                  10.61±1.71              6.80±1.01               5.24±1.42               4.63±1.81     

Data not available for all patients. hsa, *Homo sapiens*; miR, microRNA. Data are presented as mean ± standard deviation. A Student\'s t-test was used for the statistical analysis.
